Matt Taylor

“I just wanted to see if we could dig in further on the trends in tissue recon and wound recon. The presentation talks about some declines in UBM and Integra skin, so I was hoping you could unpack that further.”

“Stuart, welcome back, and I'd love to hear a little bit more about, you know, why this is the right time for this transition and any differences in your approach versus prior management in terms of how to execute on the significant priorities you have in this compliance plan and the recovery of the products that have…”

“I just wanted to know better what you were assuming for the Novum returns just so we can understand if there aren't returns, what the upside could be?”

“And I also wanted to ask about the MRI contrast agent. You mentioned some progress on that program. Could you talk about when that could actually launch? What's the timeline to get through phase two, phase three?”

“I actually wanted to ask a penal question about the tariff impact because you saw the benefit here in Q1. I guess what are you assuming for the rest of the year with regards to IEPA tariffs or tariffs in general, and what do you think could happen with the 232 investigation?”